Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs
BEDMINSTER, N.J. and DUBLIN, Ireland , March 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, announced the presentation of  a poster today at the
View HTML
Toggle Summary Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP)
BEDMINSTER , N.J. and DUBLIN, Ireland , March 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, presented an analysis showing that, consistent with
View HTML
Toggle Summary Amarin Announces Closing of Underwriter's Purchase of Additional Shares
BEDMINSTER, N.J. , and DUBLIN, Ireland , March 05, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"), it has issued 1,438,356 additional ADSs, pursuant
View HTML
Toggle Summary Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study
Study Results Anticipated to be Released by End of Q3 2018
View HTML
Toggle Summary Amarin Sponsors Multiple Scientific Presentations Scheduled for 2018 American College of Cardiology Annual Scientific Session & Expo
Presentations to Include Additional Real-World Data, Clinical and Cost Analyses of Patient Outcomes From Managed Care Databases
View HTML
Toggle Summary Amarin Reports Record Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Operations
Record Revenue of $181.1 Million and $ 53.9 Million for Full Year and Fourth Quarter 2017   REDUCE-IT Cardiovascular Outcomes Study Remains on Schedule to Report Top-Line Results Before the End of Q3 2018 Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J.
View HTML
Toggle Summary Amarin to Report Fourth Quarter and Full Year 2017 Results and Host Conference Call on February 27th, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with
View HTML
Toggle Summary Amarin Prices Public Offering of American Depositary Shares
BEDMINSTER, N.J. and DUBLIN, Ireland , Jan. 30, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the pricing of the underwritten public offering of its American Depositary Shares ("ADSs") for gross proceeds of approximately $70.0 million , before deducting the
View HTML
Toggle Summary Amarin Announces Proposed Public Offering of American Depositary Shares
BEDMINSTER, N.J. , and DUBLIN, Ireland , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a registered underwritten public offering of its American Depositary Shares.  All of the shares in the proposed offering are to be sold by Amarin.  The offering is subject
View HTML
Toggle Summary Amarin's REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events
On Track for Patient Final Study Visits to Commence in March 2018
View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation